BioCentury | Mar 2, 2018
Finance

Genome toolbox

The syndicate behind Inscripta Inc.’s $55.5 million series C round includes investors well-versed in genome reading and writing that are making a foray into genome editing. New investor Mérieux Développement and existing investor Paladin Capital...
BioCentury | Nov 3, 2017
Product Development

Liver X factor

...an exclusive license to the technology. The platform uses microRNAs as a route to discovering protein pathways...
BioCentury | Mar 1, 2017
Financial News

Muse raises $23M in series B

Genome engineering company Muse Biotechnology Inc. (Boulder, Colo.) said it raised $23 million in an oversubscribed series B round led by Venrock. Foresite Capital and Paladin Capital also participated, as did existing investors NanoDimension and...
BioCentury | Jun 16, 2016
Distillery Therapeutics

Therapeutics: G protein pathway suppressor 2 (GPRS2)

Endocrine/metabolic disease INDICATION: Obesity; diabetes Patient sample and mouse studies suggest GPRS2 could help treat obesity and Type II diabetes. GPRS2 levels were lower in visceral adipose tissue (VAT) macrophages of patients with obesity or...
BioCentury | May 13, 2013
Product Development

An association for dissociation

Forest Laboratories Inc. 's investment and option deal with Trevena Inc. last week will support the translation of a successful mechanism for treating chronic heart failure into the acute setting, as well as the development...
BioCentury | Feb 14, 2013
Distillery Techniques

Technology: Assays & screens

...shRNAs identified synergistic or suppressive genetic interactions, which led to the identification of multiple putative protein pathways...
BioCentury | Aug 2, 2012
Distillery Techniques

Technology: Markers

Approach Summary Licensing status Publication and contact information Markers Subtype-specific somatic mutations in medulloblastoma Identification of new subtype-specific somatic mutations in medulloblastoma could aid the development of new treatments for the disease. Whole-exome hybrid capture...
BioCentury | Nov 10, 2011
Cover Story

Arrestin psychosis

...G protein-coupled receptors (GPCRs) such as the D2 receptor signal not only through well-known G protein pathways...
...design a D2 receptor ligand that was biased toward activating the b-arrestin pathway over G protein pathways...
BioCentury | Jun 21, 2010
Emerging Company Profile

Trevena: Biased about pathways

Trevena Inc. believes G protein-coupled receptor ligands that target just one GPCR pathway could provide either better efficacy or fewer side effects than ligands that agonize or antagonize the whole receptor. The company is raising...
BioCentury | Sep 22, 2008
Emerging Company Profile

Proteostasis: One drug, many diseases

Emerging Company Profile Parts of the proteostasis network, such as chaperones, folding enzymes, and the proteasome and degradation processes, are well known and have been targeted by many companies seeking to treat diseases of protein...
Items per page:
1 - 10 of 46
BioCentury | Mar 2, 2018
Finance

Genome toolbox

The syndicate behind Inscripta Inc.’s $55.5 million series C round includes investors well-versed in genome reading and writing that are making a foray into genome editing. New investor Mérieux Développement and existing investor Paladin Capital...
BioCentury | Nov 3, 2017
Product Development

Liver X factor

...an exclusive license to the technology. The platform uses microRNAs as a route to discovering protein pathways...
BioCentury | Mar 1, 2017
Financial News

Muse raises $23M in series B

Genome engineering company Muse Biotechnology Inc. (Boulder, Colo.) said it raised $23 million in an oversubscribed series B round led by Venrock. Foresite Capital and Paladin Capital also participated, as did existing investors NanoDimension and...
BioCentury | Jun 16, 2016
Distillery Therapeutics

Therapeutics: G protein pathway suppressor 2 (GPRS2)

Endocrine/metabolic disease INDICATION: Obesity; diabetes Patient sample and mouse studies suggest GPRS2 could help treat obesity and Type II diabetes. GPRS2 levels were lower in visceral adipose tissue (VAT) macrophages of patients with obesity or...
BioCentury | May 13, 2013
Product Development

An association for dissociation

Forest Laboratories Inc. 's investment and option deal with Trevena Inc. last week will support the translation of a successful mechanism for treating chronic heart failure into the acute setting, as well as the development...
BioCentury | Feb 14, 2013
Distillery Techniques

Technology: Assays & screens

...shRNAs identified synergistic or suppressive genetic interactions, which led to the identification of multiple putative protein pathways...
BioCentury | Aug 2, 2012
Distillery Techniques

Technology: Markers

Approach Summary Licensing status Publication and contact information Markers Subtype-specific somatic mutations in medulloblastoma Identification of new subtype-specific somatic mutations in medulloblastoma could aid the development of new treatments for the disease. Whole-exome hybrid capture...
BioCentury | Nov 10, 2011
Cover Story

Arrestin psychosis

...G protein-coupled receptors (GPCRs) such as the D2 receptor signal not only through well-known G protein pathways...
...design a D2 receptor ligand that was biased toward activating the b-arrestin pathway over G protein pathways...
BioCentury | Jun 21, 2010
Emerging Company Profile

Trevena: Biased about pathways

Trevena Inc. believes G protein-coupled receptor ligands that target just one GPCR pathway could provide either better efficacy or fewer side effects than ligands that agonize or antagonize the whole receptor. The company is raising...
BioCentury | Sep 22, 2008
Emerging Company Profile

Proteostasis: One drug, many diseases

Emerging Company Profile Parts of the proteostasis network, such as chaperones, folding enzymes, and the proteasome and degradation processes, are well known and have been targeted by many companies seeking to treat diseases of protein...
Items per page:
1 - 10 of 46